Speech Entrainment for Aphasia Recovery

NCT ID: NCT04364854

Last Updated: 2025-11-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-21

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

After a stroke, many people experience a language impairment called aphasia. One of the most debilitating types of aphasia is non-fluent aphasia. Non-fluent aphasia is defined by significantly reduced speech production, with the speaker producing only a few words or even less. Speech entrainment therapy (SET) is a treatment that has been shown to increase fluency in people with non-fluent aphasia. The study looks to define the best dose of SET that leads to sustained improvements in spontaneous speech production.

Participants who are eligible will undergo baseline language testing, an MRI, and will be randomized into one of 4 treatment groups: SET for 3 weeks, SET for 4.5 weeks, SET for 6 weeks, and no treatment (control group).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aphasia Aphasia Non Fluent Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SET (Speech Entrainment Therapy) 3 weeks

Group Type EXPERIMENTAL

SET (Speech Entrainment Therapy) 3 weeks

Intervention Type BEHAVIORAL

3 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program

SET (Speech Entrainment Therapy) 4.5 weeks

Group Type EXPERIMENTAL

SET (Speech Entrainment Therapy) 4.5 weeks

Intervention Type BEHAVIORAL

4.5 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program

SET (Speech Entrainment Therapy) 6 weeks

Group Type EXPERIMENTAL

SET (Speech Entrainment Therapy) 6 weeks

Intervention Type BEHAVIORAL

6 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program

No Therapy 6 weeks

Group Type OTHER

No Therapy 6 Weeks

Intervention Type OTHER

Participants will not be getting any SET for 6 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SET (Speech Entrainment Therapy) 3 weeks

3 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program

Intervention Type BEHAVIORAL

SET (Speech Entrainment Therapy) 4.5 weeks

4.5 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program

Intervention Type BEHAVIORAL

SET (Speech Entrainment Therapy) 6 weeks

6 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program

Intervention Type BEHAVIORAL

No Therapy 6 Weeks

Participants will not be getting any SET for 6 weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aphasia as a result of a left hemisphere ischemic or hemorrhagic stroke (WAB-R Aphasia Quotient \<93.8).
* Presence of left hemisphere stroke in clinical imaging (CT/MRI) and NIHSS
* Participants must have spoken English as their primary language.
* 21-81 years old
* Pre-stroke modified Rankin Scale (mRS)= 2 or less
* Post-stroke mRS= 4 or less.
* At least 6 months post-stroke.
* Non-fluent aphasia (WAB-R Comprehension score \>4 and WAB-R Fluency score \<6).
* Technological compatibility (to be determined by clinical judgment of SLP)

Exclusion Criteria

* History of chronic neurological or psychiatric diseases (excluding migraines, depression, or post-stroke epilepsy). Self-reported history of learning disability.
* Severe dysarthria (determined via SLP clinical judgment from spontaneous speech tasks on the ASRS 3.0).
* Global aphasia.
* History of right-hemisphere strokes or brain stem/cerebellar strokes with persistent deficits (as evidenced by MRI/CT and NIHSS).
* Uncorrectable hearing as determined by the SLP's clinical judgment.
* Uncorrectable vision.
* Contraindications to MRI or inability to complete the MRI scanning session.
* Women who are pregnant.
Minimum Eligible Age

21 Years

Maximum Eligible Age

81 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Deafness and Other Communication Disorders (NIDCD)

NIH

Sponsor Role collaborator

Medical University of South Carolina

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Leonardo Bonilha, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Emory University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

University of South Carolina

Columbia, South Carolina, United States

Site Status

University of Utah

Salt Lake City, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U01DC017521-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

00091924

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MIT Intensive Treatment Study
NCT06213376 COMPLETED NA